Grant of Options
27/06/2024 09:05
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240627:nRSa1489Ua&default-theme=true
RNS Number : 1489U Alliance Pharma PLC 27 June 2024
For immediate release 27 June 2024
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Grant of Options to Directors
Alliance Pharma plc (AIM: APH), the international healthcare group, announces
that the Board has issued options over 906,862 ordinary shares of 1 pence each
in the Company, on the recommendation of the Company's Remuneration Committee,
to Nick Sedgwick, pursuant to the Company's Long-Term Incentive Plan 2019.
The awards have been granted at nil-cost and become exercisable on 24 June
2027 subject always to continued employment and the satisfaction of
performance conditions based on EPS, TSR and ROCE targets.
The notification below, made in accordance with the requirements of the UK
Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person discharging
managerial responsibilities.
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Mr Nick Sedgwick
2 Reason for the notification
a) Position/status Chief Executive Officer - PDMR
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Alliance Pharma plc
b) Legal Entity Identifier N/A
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 1.0 pence each
Identification code
ISIN: GB0031030819
b) Nature of the transaction Grant of Options
c) Currency GBP
d) Price(s) and volume(s) Exercise Price (p) No. of share options
Nil 906,862
e) Aggregated information Grant of 906,862 options to acquire ordinary shares of 1 pence each at
nil-cost.
- Aggregated volume
- Price
- Aggregated total
f) Date of the transaction 24 June 2024
g) Place of the transaction Outside of trading venue
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Head of Investor Relations: Cora McCallum + 44 (0)1249 705168
ir@allianceph.com (mailto:ir@allianceph.com)
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills
alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)
Numis Securities Limited (Nominated Adviser and Joint Broker) + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc (Joint Broker) + 44 (0)20 7597 5970
Patrick Robb / Maria Gomez de Olea
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands. For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGIGDLSGDDGSR